Boston Scientific Corp. is set to strengthen its atrial fibrillation (AF) treatment offerings by acquiring Apama Medical Inc. in a deal that could be worth up to $300 million. The transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018 to 2020 based on achievements of clinical and regulatory milestones. The deal is set to close in 4Q17.